JP2001511187A - 選択的免疫ダウンレギュレーション(sidr)を行う新規プロセス - Google Patents
選択的免疫ダウンレギュレーション(sidr)を行う新規プロセスInfo
- Publication number
- JP2001511187A JP2001511187A JP53778198A JP53778198A JP2001511187A JP 2001511187 A JP2001511187 A JP 2001511187A JP 53778198 A JP53778198 A JP 53778198A JP 53778198 A JP53778198 A JP 53778198A JP 2001511187 A JP2001511187 A JP 2001511187A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- subject
- rats
- sidr
- immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.被験体において感染性細菌性物質に対する選択的免疫ダウンレギュレーショ ンを生成するためのプロセスであって、選択的免疫ダウンレギュレーションを生 成し得、かつ該感染性物質の成分またはそのフラグメントを含む試薬または試薬 の組合せを該被験体に導入する工程を包含する、プロセス。 2.前記感染性細菌性物質が連鎖球菌を含む、請求項1に記載のプロセス。 3.前記連鎖球菌が、リウマチ熱または糸球体腎炎の原因物質である、請求項2 に記載のプロセス。 4.以下の工程を包含する移植プロセス: MHCクラスI、MHCクラスII、および組織適合性因子からなる群より選択される メンバー、または任意の前記のものの組合せを含むドナー抗原に対する選択的免 疫ダウンレギュレーションをレシピエント被験体において確立する工程;および 該レシピエント被験体に、該ドナー由来の細胞、組織、もしくは器官、または それらの成分を導入する工程。 5.以下の工程を包含する移植プロセス: レシピエント抗原に対する選択的免疫ダウンレギュレーションをドナーにおい て確立する工程であって、該確立が、該レシピエント由来の細胞、組織、器官、 またはそれらの成分を該ドナーに導入し、それにより、細胞、組織、器官、また はそれらの成分を該ドナーに移植する前に、該レシピエント抗原に対する選択的 免疫ダウンレギュレーションを該ドナーにおいて確立することによって行われる 、工程;および その後に、該レシピエントに、選択的ダウン免疫レギュレーションを有する該 ドナー由来の細胞、組織、器官、またはそれらの成分を移植する工程。 6.前記レシピエント抗原が、免疫細胞、骨髄細胞、およびT細胞、または任意 の前記のものの組合せからなる群より選択される、請求項5に記載の移植プロセ ス。 7.前記レシピエントの細胞、組織、もしくは器官、または成分が、免疫細胞ま たは骨髄細胞またはT細胞からなる群より選択される、請求項5に記載の移植プ ロセス。 8.前記ドナー抗原が、MHCクラスI、MHCクラスII、および組織適合性因子、ま たは任意の前記のものの組合せからなる群より選択されるメンバーを含む、請求 項5に記載の移植プロセス。 9.被験体におけるクローン病を処置するためのプロセスであって、同種間供給 源、異種間供給源、および自己供給源、ならびに免疫学的等価物またはこれらの 組合せに由来する成分、細胞、組織、または器官を該被験体に導入することによ り、炎症性の腸に対する選択的免疫ダウンレギュレーションを該被験体において 確立する工程を包含する、プロセス。 10.膵臓細胞、インスリンレセプター、脂肪細胞、および肝臓細胞、またはこ れらの成分からなる群より選択されるメンバーを含む非インスリンエピトープに 対する選択的免疫ダウンレギュレーションを被験体において確立することにより 、該被験体において糖尿病を処置する方法であって、該エピトープは、同種間供 給源、異種間供給源、および自己供給源、ならびに免疫学的等価物またはそれら の組合せから選択される供給源に由来する、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80862997A | 1997-02-28 | 1997-02-28 | |
US08/808,629 | 1997-02-28 | ||
PCT/US1998/003606 WO1998037917A1 (en) | 1997-02-28 | 1998-02-26 | Novel processes implementing selective immune down regulation (sidr) |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007062690A Division JP2007145871A (ja) | 1997-02-28 | 2007-03-12 | 選択的免疫ダウンレギュレーション(sidr)を行う新規プロセス |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001511187A true JP2001511187A (ja) | 2001-08-07 |
JP2001511187A5 JP2001511187A5 (ja) | 2004-10-28 |
Family
ID=25199306
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53778198A Pending JP2001511187A (ja) | 1997-02-28 | 1998-02-26 | 選択的免疫ダウンレギュレーション(sidr)を行う新規プロセス |
JP2007062690A Withdrawn JP2007145871A (ja) | 1997-02-28 | 2007-03-12 | 選択的免疫ダウンレギュレーション(sidr)を行う新規プロセス |
JP2010276299A Withdrawn JP2011046753A (ja) | 1997-02-28 | 2010-12-10 | 選択的免疫ダウンレギュレーション(sidr)を行う新規プロセス |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007062690A Withdrawn JP2007145871A (ja) | 1997-02-28 | 2007-03-12 | 選択的免疫ダウンレギュレーション(sidr)を行う新規プロセス |
JP2010276299A Withdrawn JP2011046753A (ja) | 1997-02-28 | 2010-12-10 | 選択的免疫ダウンレギュレーション(sidr)を行う新規プロセス |
Country Status (6)
Country | Link |
---|---|
US (2) | US20040022768A1 (ja) |
EP (2) | EP2301567A1 (ja) |
JP (3) | JP2001511187A (ja) |
CA (1) | CA2252790A1 (ja) |
IL (3) | IL126714A (ja) |
WO (1) | WO1998037917A1 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2252790A1 (en) * | 1997-02-28 | 1998-09-03 | Enzo Therapeutics, Inc. | Novel processes implementing selective immune down regulation (sidr) |
US8703480B1 (en) | 1997-03-21 | 2014-04-22 | Enzo Therapeutics, Inc. | Biological function effecting viral vectors and chimeric cells useful as packaging cell lines and target cells |
EP1005561A4 (en) | 1997-03-21 | 2004-03-31 | Enzo Therapeutics Inc A Fully | VECTOR, VIRAL VECTORS AND PACKAGING CELL LINES TO THEIR REPRODUCTION |
CA2313899A1 (en) * | 1999-07-16 | 2001-01-16 | Enzo Therapeutics, Inc. | Novel selective imune down regulation (sidr) mediated transplantation processes, processes for preventing or treating diseases in a subject, and compositions of matter comprising trained or programmed cells, tissues or organs useful for sidr establishment |
IL142802A (en) * | 2000-04-27 | 2015-01-29 | Enzo Therapeutics Inc | Use of one or more HBV antigens for the preparation of oral pharmaceutical preparations for the treatment of a person with active HBV infection or hepatocellular carcinoma |
US20030170258A1 (en) * | 2001-05-09 | 2003-09-11 | Enzo Therapeutics, Inc. | Novel processes implementing selective immune down regulation (SIDR) |
US7485314B2 (en) * | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
US20040171522A1 (en) * | 2003-02-27 | 2004-09-02 | Yaron Ilan | Regulation of immune responses by manipulation of intermediary metabolite levels |
US9717754B2 (en) | 2003-02-27 | 2017-08-01 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
US20070184058A1 (en) * | 2003-02-27 | 2007-08-09 | Yaron Ilan | Glucocerebroside treatment of pulmonary or respiratory diseases or disorders |
WO2005032462A2 (en) * | 2003-02-27 | 2005-04-14 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
US20050069546A1 (en) | 2003-09-30 | 2005-03-31 | Yaron Ilan | Educated NKT cells and their uses in the treatment of immune-related disorders |
US7364758B2 (en) * | 2004-08-31 | 2008-04-29 | Shih-Lan Hsu | Pharmaceutical use of Graptopetalum and related plants |
US7588776B2 (en) | 2004-08-31 | 2009-09-15 | Shih-Lan Hsu | Pharmaceutical use of water-soluble fraction of Graptopetalum |
CN102112491A (zh) * | 2008-06-06 | 2011-06-29 | 贝勒研究院 | 抗-cd8抗体阻断细胞毒素效应物的引发并导致调节性cd8+t细胞的产生 |
DE102015225578A1 (de) * | 2015-12-17 | 2017-06-22 | Robert Bosch Gmbh | Vorrichtung zum Empfangen von Mikrowellenstrahlung |
TW201911653A (zh) * | 2017-08-03 | 2019-03-16 | 廣達電腦股份有限公司 | 雙頻帶天線結構 |
CN109355300B (zh) * | 2018-11-26 | 2022-01-28 | 成都中医药大学 | 黄连sdir转录因子在提高植物抗旱中的应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4322405A (en) * | 1981-04-06 | 1982-03-30 | Laboratoires Om Societe Anonyme | Method for treating rheumatoid arthritis |
US4950469A (en) * | 1986-05-30 | 1990-08-21 | La Jolla Pharmaceutical Company | D-GL conjugate therapy |
US5399347A (en) * | 1987-06-24 | 1995-03-21 | Autoimmune, Inc. | Method of treating rheumatoid arthritis with type II collagen |
US5350671A (en) * | 1987-11-18 | 1994-09-27 | Chiron Corporation | HCV immunoassays employing C domain antigens |
DE69033975T2 (de) * | 1989-01-23 | 2002-10-02 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Rekombinanttherapien für Infektionen und hyperproliferative Störungen |
ES2085983T3 (es) * | 1989-12-20 | 1996-06-16 | Schering Corp | Antagonistas de anticuerpos de la interleuquina-4 humana. |
IL99699A (en) * | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
IL99864A (en) * | 1990-10-31 | 2000-11-21 | Autoimmune Inc | Compositions for suppressing transplant rejection in mammals which contain tissue donor derived MHC antigens |
AU688736B2 (en) * | 1992-08-10 | 1998-03-19 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Interleukin-4 stimulated T lymphocyte cell death |
DK1438970T3 (da) * | 1993-03-19 | 2008-12-15 | D Allen Allen | Fremgangsmåde til at inhibere HIV-associerede sygdomme ved hjælp af monoklonale antistoffer rettet mod sig-selv-rettede cytotoksiske celler |
US5681571A (en) * | 1993-10-08 | 1997-10-28 | Duotol Ab | Immunological tolerance-inducing agent |
WO1995027500A1 (en) * | 1994-04-08 | 1995-10-19 | Brigham And Women's Hospital | TREATMENT OF AUTOIMMUNE DISEASE USING ORAL TOLERIZATION AND/OR Th2-ENHANCING CYTOKINES |
BR9507451A (pt) * | 1994-04-08 | 1997-08-05 | Brigham & Womens Hospital | Composição farmacêutica uso de uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo e produto contendo uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo |
US5849285A (en) * | 1994-04-13 | 1998-12-15 | Research Corporation Technologies, Inc. | Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells |
US5872154A (en) * | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
CA2252790A1 (en) * | 1997-02-28 | 1998-09-03 | Enzo Therapeutics, Inc. | Novel processes implementing selective immune down regulation (sidr) |
US20030170258A1 (en) * | 2001-05-09 | 2003-09-11 | Enzo Therapeutics, Inc. | Novel processes implementing selective immune down regulation (SIDR) |
-
1998
- 1998-02-26 CA CA002252790A patent/CA2252790A1/en not_active Abandoned
- 1998-02-26 WO PCT/US1998/003606 patent/WO1998037917A1/en active Application Filing
- 1998-02-26 EP EP10184206A patent/EP2301567A1/en not_active Withdrawn
- 1998-02-26 JP JP53778198A patent/JP2001511187A/ja active Pending
- 1998-02-26 IL IL126714A patent/IL126714A/en not_active IP Right Cessation
- 1998-02-26 EP EP98912887.1A patent/EP0914163B1/en not_active Expired - Lifetime
-
2003
- 2003-03-04 US US10/377,628 patent/US20040022768A1/en not_active Abandoned
- 2003-03-04 US US10/377,603 patent/US20040023909A1/en not_active Abandoned
-
2007
- 2007-03-12 JP JP2007062690A patent/JP2007145871A/ja not_active Withdrawn
- 2007-07-18 IL IL184691A patent/IL184691A0/en not_active IP Right Cessation
-
2010
- 2010-12-08 IL IL209847A patent/IL209847A0/en unknown
- 2010-12-10 JP JP2010276299A patent/JP2011046753A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
IL126714A0 (en) | 1999-08-17 |
WO1998037917A1 (en) | 1998-09-03 |
IL209847A0 (en) | 2011-02-28 |
EP2301567A1 (en) | 2011-03-30 |
IL126714A (en) | 2010-12-30 |
EP0914163A1 (en) | 1999-05-12 |
US20040022768A1 (en) | 2004-02-05 |
JP2011046753A (ja) | 2011-03-10 |
EP0914163A4 (en) | 2001-08-16 |
JP2007145871A (ja) | 2007-06-14 |
IL184691A0 (en) | 2007-12-03 |
EP0914163B1 (en) | 2016-02-24 |
CA2252790A1 (en) | 1998-09-03 |
US20040023909A1 (en) | 2004-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011046753A (ja) | 選択的免疫ダウンレギュレーション(sidr)を行う新規プロセス | |
Ilan et al. | Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors. | |
BE1023915A9 (fr) | Nouveaux procedes pour induire une reponse immunitaire | |
Ilan et al. | Oral tolerization to adenoviral proteins permits repeated adenovirus‐mediated gene therapy in rats with pre‐existing immunity to adenoviruses | |
WO1998037917A9 (en) | Novel processes implementing selective immune down regulation (sidr) | |
US20150190505A1 (en) | Live and in-vivo tumor specific cancer vaccine system developed by co-administration of either at least two or all three of the following components such as tumor cells, an oncolytic virus vector with transgenic expression of gm-csf and an immune checkpoint modulator | |
EP1001815B1 (fr) | Vecteurs derives d'anticorps pour le transfert de substances dans les cellules | |
JP2002515734A (ja) | 遺伝子改変された樹状細胞により媒介される免疫刺激 | |
HU230488B1 (hu) | Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására | |
US5681556A (en) | Method and compositions for suppressing allograft rejection in mammals | |
JP2013507970A (ja) | 細胞ベースの抗癌組成物ならびに当該物の製造方法および使用方法 | |
US20040087485A1 (en) | Educated nkt cells and their uses in the treatment of immune-related disorders | |
Plaksin et al. | Effective anti‐metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV) | |
Yamamoto et al. | Genetic control of granuloma response to oil-associated BCG cell wall vaccine in mice | |
Willimsky et al. | Interleukin-7/B7. 1-encoding adenoviruses induce rejection of transplanted but not nontransplanted tumors | |
US20030170258A1 (en) | Novel processes implementing selective immune down regulation (SIDR) | |
Wakabayashi et al. | Suppression of an already established tumor growing through activated mucosal CTLs induced by oral administration of tumor antigen with cholera toxin | |
AU2018250926B2 (en) | Methods to produce peptides, polypeptides or cells for modulating immunity | |
JP2007533633A (ja) | 教育済みnkt細胞及び免疫関連の障害の治療におけるその使用 | |
Karanikas et al. | Autoreactive cytotoxic T cells in mice are induced by immunization with a conserved mitochondrial enzyme in Freund’s complete adjuvant | |
JP2001172187A (ja) | 新規の選択的免疫ダウンレギュレーション(sidr)媒介性移植プロセス、被験体における疾患を予防または処置するためのプロセス、およびsidrを確立するために有用である、馴化またはプログラミングされた細胞、組織または器官を含む組成物 | |
Couty et al. | Delivery of mengovirus-derived RNA replicons into tumoural liver enhances the anti-tumour efficacy of a peripheral peptide-based vaccine | |
CN115867299A (zh) | 用于预防或治疗癌症的药物组合物 | |
EA042634B1 (ru) | СРЕДСТВО ДЛЯ ИНДУКЦИИ СПЕЦИФИЧЕСКОГО ИММУНИТЕТА ПРОТИВ ВИРУСА ТЯЖЕЛОГО ОСТРОГО РЕСПИРАТОРНОГО СИНДРОМА SARS-CoV-2 В ЛИОФИЛИЗИРОВАННОЙ ФОРМЕ (ВАРИАНТЫ) | |
JPWO2021164753A5 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070312 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090216 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090514 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20090521 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110520 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110531 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110622 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110704 |